PMC:7534795 / 38333-38530 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T301","span":{"begin":4,"end":7},"obj":"Disease"},{"id":"T302","span":{"begin":64,"end":67},"obj":"Disease"},{"id":"T303","span":{"begin":96,"end":108},"obj":"Disease"}],"attributes":[{"id":"A301","pred":"mondo_id","subj":"T301","obj":"http://purl.obolibrary.org/obo/MONDO_0012733"},{"id":"A302","pred":"mondo_id","subj":"T302","obj":"http://purl.obolibrary.org/obo/MONDO_0012733"},{"id":"A303","pred":"mondo_id","subj":"T303","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"}],"text":"CEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No differenc"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T296","span":{"begin":16,"end":21},"obj":"Chemical"}],"attributes":[{"id":"A296","pred":"chebi_id","subj":"T296","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"CEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No differenc"}

{"project":"LitCovid-sentences","denotations":[{"id":"T274","span":{"begin":50,"end":182},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"CEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No differenc"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T150","span":{"begin":96,"end":108},"obj":"Phenotype"}],"attributes":[{"id":"A150","pred":"hp_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"CEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No differenc"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1214","span":{"begin":96,"end":108},"obj":"Disease"},{"id":"1215","span":{"begin":145,"end":154},"obj":"Disease"}],"attributes":[{"id":"A1214","pred":"tao:has_database_id","subj":"1214","obj":"MESH:D006973"},{"id":"A1215","pred":"tao:has_database_id","subj":"1215","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"CEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).\n• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).\n• No differenc"}